one
gene
strongli
induc
type
interferon
first
ubiquitinlik
modifi
ubl
identifi
blomstrom
et
al
haa
et
al
analog
ubiquitin
ubl
like
small
ubiquitinrel
modifi
sumo
human
leukocyt
antigen
hla
f
adjac
transcript
neural
precursor
cell
express
development
downregul
coval
link
target
protein
alter
varieti
biolog
process
compos
two
ubl
domain
connect
flexibl
polypeptid
hing
region
domain
form
four
singl
narasimhan
et
al
reminisc
ubiquitin
structur
ctermin
tail
contain
lrlrgg
motif
essenti
conjug
target
protein
like
ubiquitin
coval
attach
lysin
residu
target
protein
group
via
lrlrgg
motif
loeb
haa
analog
ubiquitin
conjug
system
isgyl
mediat
consecut
action
threestep
catalyt
cascad
enzym
induc
type
ifn
figur
enzym
bind
ub
mediat
form
complex
catalyz
ub
ctermin
acyl
adenyl
tokgoz
et
al
subsequ
catalyt
cystein
enzym
interact
ubiquitinamp
complex
undergo
acyl
substitut
lead
thioester
bond
format
releas
amp
group
transthiol
reaction
cystein
residu
replac
enzym
enzym
catalyz
isopeptid
bond
format
also
contribut
substrat
specif
enzym
bind
thioester
recogn
protein
substrat
catalyz
transfer
ubiquitin
enzym
target
protein
zhang
zhang
sharp
contrast
ubiquitin
highli
conserv
among
differ
speci
amino
acid
aa
composit
effector
function
differ
substanti
among
speci
identifi
vertebr
murin
human
counterpart
share
homolog
similar
aa
level
like
caus
high
evolutionari
pressur
antipathogen
immun
effector
function
need
adapt
immun
evas
mechan
rapidli
mutat
pathogen
one
featur
substanti
differ
isgyl
mechan
murin
human
use
certain
enzym
ubiquitinactiv
enzym
homolog
common
enzym
human
mous
system
kim
et
al
wherea
counterpart
ubiquitin
ubiquitinlik
modifi
activ
enzym
ubiquitinlik
modifi
activ
enzym
pelzer
et
al
enzym
repres
human
murin
conjug
enzym
isgyl
respect
share
aa
ident
wherea
conjug
enzym
ubl
system
show
ident
kim
et
al
also
interact
enzym
ub
conjug
system
indic
overlap
conjug
system
level
enzym
zhao
et
al
howev
enzym
ubiquitinconjug
enzym
repres
domin
conjug
enzym
ubiquitin
km
valu
uncov
higher
affin
compar
durfe
et
al
four
cellular
ligas
identifi
far
human
ligas
murin
counterpart
ligas
domin
ligas
isgyl
coordin
conjug
substrat
interestingli
conjug
either
wong
et
al
ketscher
et
al
furthermor
ubiquitinprotein
ligas
estrogenrespons
finger
protein
efp
zou
zhang
human
homolog
drosophila
hhari
okumura
et
al
tripartit
motifcontain
protein
park
et
al
also
report
mediat
isgyl
shown
isgyl
occur
cotransl
process
favor
modif
newli
synthes
protein
infect
cell
mainli
viral
protein
translat
isgyl
interfer
pathogen
protein
function
shown
capsid
assembl
papilloma
viru
durfe
et
al
furthermor
cellular
protein
involv
antivir
defens
export
viral
particl
shown
isgyl
perng
lenschow
ubiquitin
ublconjug
pathway
revers
action
deubiquitin
enzym
dub
proteas
remov
trim
ububl
residu
target
protein
endogen
proteas
usp
famili
recogn
deconjug
ubiquitin
howev
small
group
protein
usp
famili
report
show
crossreact
deconjug
ubiquitin
case
catic
et
al
ye
et
al
baster
et
al
addit
mani
virus
bacteria
evolv
way
revok
isgyl
immun
evas
mechan
exampl
viral
proteas
found
middl
east
respiratori
syndrom
coronaviru
merscov
mielech
et
al
crimeancongo
hemorrhag
fever
viru
cchfv
friasstah
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
beke
et
al
encod
papainlik
proteas
plp
impair
host
innat
immun
respons
contrast
crossreact
isopeptidas
endogen
proteas
show
reactiv
toward
ubiquitin
malakhov
et
al
baster
et
al
ronau
et
al
repres
major
isopeptidas
vivo
ketscher
et
al
order
defin
structur
function
relationship
specif
baster
et
al
identifi
molecular
determin
solv
crystal
structur
mous
alon
complex
mous
specif
toward
mediat
small
interact
interfac
two
defin
area
within
sequenc
term
respect
interact
hydrophob
contact
side
chain
stabliz
stack
contact
aromat
aa
region
compris
residu
form
hydrophob
pocket
specif
accommod
bulki
aromat
side
chain
furthermor
side
chain
contribut
stabil
note
replac
residu
correspond
region
homolog
residu
ubiquitin
specif
proteas
result
lower
affin
toward
within
region
residu
interact
residu
hydrogen
bond
likewis
replac
residu
correspond
region
homolog
residu
ubiquitin
specif
proteas
result
lower
affin
toward
moreov
ctermin
domain
aa
residu
necessari
suffici
bind
activ
structur
data
demonstr
ctermin
ntermin
ubl
domain
bind
vitro
assay
reveal
cleav
ctermin
domain
effect
cleav
fulllength
baster
et
al
independ
deconjug
activ
bind
receptor
complex
compet
janu
kinas
therebi
neg
regul
type
ifn
signal
malakhova
et
al
remark
requir
signal
transduc
activ
transcript
exert
inhibitori
effect
ifn
signal
ifnstimul
gene
express
arimoto
et
al
figur
human
bind
free
prevent
proteasom
degrad
sphase
kinaseassoci
protein
thu
critic
ensur
neg
regul
immun
stabil
tokarz
et
al
zhang
et
al
howev
murin
appear
influenc
stabil
mous
ifnar
signal
underlin
speci
specif
peculiar
knobeloch
et
al
osiak
et
al
zhang
et
al
unconjug
form
report
releas
cell
exert
cytokin
like
activ
although
leader
signal
sequenc
direct
secret
shown
certain
cell
type
capabl
releas
extracellular
space
cell
type
epithelialderiv
cell
line
fibroblast
monocyt
neutrophil
lymphocyt
knight
cordova
bogunov
et
al
sun
et
al
extracellular
detect
media
cell
well
serum
patient
treat
dcunha
et
al
earli
work
suggest
secret
elicit
secret
lymphocyt
recht
et
al
bacillu
bcg
also
induc
secret
control
peripher
blood
mononuclear
cell
pbmc
stimul
recombin
human
bogunov
et
al
normal
control
patient
extracellular
interleukin
il
play
synergist
role
stimul
releas
natur
killer
nk
cell
lymphocyt
secret
respons
bogunov
et
al
howev
secret
detect
pbmc
patient
defect
lead
suscept
mycobacteri
diseas
autoinflamm
bogunov
et
al
recent
adhes
molecul
leukocyt
function
associ
identifi
receptor
extracellular
swaim
et
al
figur
identifi
receptor
ubiquitinactiv
interact
trap
ubait
employ
oconnor
et
al
mani
research
focus
effort
studi
character
ubiquitin
system
hershko
ciechanov
ubiquitinproteasom
system
up
repres
main
mechan
protein
degrad
regul
everi
step
within
mechan
crucial
prevent
sever
disord
diseas
tumor
develop
progress
recent
exampl
exist
drug
target
ubiquitin
system
adenosin
sulfam
inhibitor
inhibit
ubiquitin
activ
enzym
hyer
et
al
enter
phase
trial
studi
treatment
patient
relaps
refractori
acut
myeloid
leukemia
refractori
myelodysplast
syndrom
chronic
myelomonocyt
leukemia
two
compound
describ
target
cell
permeabl
inhibitor
block
catalyt
cystein
yang
et
al
panepophenanthrin
fungal
product
inhibit
ubiquitin
thioester
format
sekizawa
et
al
pyrazolidin
compound
benzoic
acid
ethyl
ester
shown
inhibit
likewis
analog
drug
carri
pyrazolidin
pharmacophor
also
inhibit
activ
therefor
subsequ
transfer
ubiquitin
enzym
effect
result
tumor
growth
delay
mous
model
leukemia
xu
et
al
besid
ubiquitin
activ
enzym
nae
inhibitor
character
nucleotid
analog
bind
enzym
inhibit
nae
function
cell
suppress
growth
human
tumor
xenograft
chemic
enter
phase
ii
studi
promis
result
anticanc
drug
acut
myelogen
leukemia
aml
highgrad
myelodysplast
syndrom
md
souci
et
al
drug
work
alloster
inhibitor
human
ubiquitinconjug
enzym
ceccarelli
et
al
bind
caus
secondari
structur
rearrang
prevent
ubiquitin
transfer
substrat
case
ubiquitin
thioester
format
compromis
neither
interact
enzym
henc
show
import
enzymat
step
regul
point
process
ubiquitin
addit
develop
target
ubiquitinconjug
enzym
variant
enzym
block
ubiquitin
transfer
substrat
pulvino
et
al
furthermor
bay
interact
ubiquitinconjug
enzym
n
modifi
reactiv
cystein
residu
enzym
strickson
et
al
analog
ubiquitin
ubl
modif
system
cascad
conjug
enzym
compris
target
affect
isgyl
likewis
inhibit
see
repres
strategi
stabil
isgyl
furthermor
cell
surfac
receptor
repres
target
modul
function
indic
also
exist
unconjug
protein
propos
function
cytokin
swaim
et
al
cell
surfac
receptor
heterodimer
complex
compris
two
subunit
domain
form
part
bind
site
intercellular
adhes
molecul
shimaoka
et
al
howev
determin
domain
recogn
differ
biochem
biolog
separ
swaim
et
al
extracellular
play
import
role
secret
cytokin
therefor
potenti
exploit
boost
cytokin
secret
swaim
et
al
contrast
target
receptor
specif
one
two
heterodim
form
receptor
would
conceptu
lessen
impact
extracellular
activ
block
receptor
activitybas
probe
abp
help
tool
studi
activ
dub
ublspecif
proteas
one
main
advantag
use
abp
substratebas
probe
abp
coval
attach
activ
site
target
protein
ovaa
verdo
verhelst
mani
proteas
secret
inact
form
requir
posttransl
modif
becom
activ
modif
either
irrevers
via
proteolysi
revers
ph
chang
protein
complex
format
hew
et
al
character
dub
biolog
process
benefit
abp
protein
activ
rather
import
classic
method
western
blot
proteom
techniqu
suitabl
deduc
enzym
activ
furthermor
fluorogen
substrat
valuabl
tool
kinet
studi
turn
target
enzym
consequ
result
fluoresc
signal
proport
enzym
activ
mention
specif
deconjug
substrat
malakhov
et
al
specif
abp
proteas
develop
ekkebu
et
al
baster
et
al
analog
abp
ubiquitin
probe
synthes
replac
ctermin
residu
electrophil
moieti
vinyl
methyl
sulfon
vme
vinyl
methyl
ester
prg
propargylamid
ekkebu
et
al
baster
et
al
probe
work
ctermin
electrophil
trap
synthes
intein
chemistri
hemelaar
et
al
figur
use
probe
repres
valuabl
tool
evalu
enzymat
activ
dub
coval
bind
activesit
cystein
via
thioether
bond
form
coval
complex
sulfur
atom
activesit
cystein
dub
interact
carbon
atom
vme
moieti
form
thiol
bond
boudreaux
et
al
form
coval
adduct
via
michaeltyp
addit
vinyl
sulfon
reaction
perform
physiolog
condit
eg
aqueou
media
slightli
alkalin
ph
preserv
biolog
function
protein
moralessanfruto
et
al
result
format
coval
complex
reaction
result
coval
adduct
detect
sdspage
upward
shift
molecular
mass
similar
experi
conduct
make
use
equival
propargylamid
probe
complex
format
form
vinyl
thioether
dub
activ
site
cystein
residu
reaction
depend
direct
nucleophil
attack
intern
alkyn
carbon
result
develop
carbanion
stabil
oxyanion
hole
activ
site
ekkebu
et
al
hew
et
al
convers
ubv
ubprg
react
demonstr
exert
enzymat
activ
toward
ubiquitin
baster
et
al
crystal
structur
mous
complex
mous
display
extens
interact
ctermin
ubl
domain
palm
thumb
domain
baster
et
al
good
exampl
use
probe
valid
ctermin
domain
necessari
suffici
bind
either
ctermin
ubl
domain
fulllength
fuse
prg
form
respect
probe
probe
react
activ
site
cystein
form
coval
complex
furthermor
cleav
effect
cleav
fulllength
cellular
substrat
baster
et
al
synthesi
ctermin
ubl
domain
carri
solidphas
peptid
chemistri
spp
briefli
spp
autom
synthesi
method
use
product
synthet
peptid
technolog
allow
assembl
peptid
chain
success
reaction
amino
acid
deriv
activ
carboxyl
moieti
incom
amino
acid
link
group
subsequ
amino
acid
new
group
get
protect
fmoc
avoid
unintend
peptid
bond
format
site
incom
amino
acid
ad
sequenc
addit
reactiv
side
chain
amino
acid
protect
ester
ether
urethan
deriv
complex
format
synthesi
synthet
peptid
el
oualid
et
al
recent
synthesi
ntermin
domain
togeth
ctermin
domain
compris
amino
acid
protein
report
xin
et
al
function
especi
relat
deisgyl
attribut
ctermin
domain
full
length
synthesi
elucid
specif
role
associ
ntermin
domain
within
highthroughput
drug
screen
ht
studi
combin
enzymat
assay
use
ubamc
extens
use
identif
small
molecul
inhibit
usp
proteas
activ
hirayama
et
al
hydrolysi
fluorophor
amc
group
upon
cleavag
isopeptidas
bond
specif
protein
result
quantifi
fluoresc
signal
use
demonstr
activ
specif
toward
baster
et
al
figur
therefor
probe
also
use
monitor
activ
deisgylas
eg
viral
dub
repres
fluoresc
polar
fp
assay
reagent
quench
green
fluoresc
rhodamin
cation
dye
cterminu
substrat
synthes
tamra
label
dipeptid
linkag
ctermin
gli
ly
side
chain
resembl
natur
substrat
precis
tirat
et
al
geurink
et
al
swatek
et
al
likewis
hydrolysi
tamralysgli
complex
specif
protein
result
quantifi
fluoresc
signal
henc
incub
led
dosedepend
decreas
polar
valu
millipolar
indic
proteolyt
cleavag
substrat
baster
et
al
figur
revers
aldehyd
inhibitor
yield
stabl
adduct
enzym
still
repres
highli
specif
inhibitor
isopeptidas
siklo
et
al
figur
probe
block
hydrolysi
chain
substrat
protein
vitro
howev
aldehyd
inhibitor
suffer
metabol
oxidationreduct
modif
phdepend
hydrat
format
result
defici
stabil
bioavail
drawback
limit
progress
aldehyd
inhibitor
clinic
due
critic
role
system
antimicrobi
host
defens
appeal
exploit
endogen
effector
system
therapeut
within
context
human
patient
lack
function
repres
valuabl
subject
investig
defin
physiolog
molecular
function
six
patient
case
defici
three
nonrel
famili
report
bogunov
et
al
zhang
et
al
mice
play
import
role
host
respons
viral
infect
shown
protect
viralinduc
lethal
use
differ
pathogen
perng
lenschow
howev
patient
appear
suscept
viral
infect
bogunov
et
al
convers
defici
patient
even
show
enhanc
antivir
protect
speer
et
al
three
defici
patient
suffer
seizur
display
intracrani
calcif
common
phenotyp
patient
syndrom
ag
zhang
et
al
human
bind
free
prevent
proteasom
degrad
tokarz
et
al
critic
ensur
neg
regul
immun
stabil
zhang
et
al
three
defici
individu
show
hyperrespons
typei
ifn
stimul
due
fact
human
stabil
reli
heavili
human
thu
absenc
would
longer
abl
function
neg
regul
typei
ifn
signal
zhang
et
al
regulatori
function
stabil
seen
mice
speer
et
al
recent
defici
patient
identifi
meuwissen
et
al
patient
life
expect
quit
short
die
shortli
birth
due
massiv
dysregul
typei
ifn
signal
five
pseudotorch
syndrom
pt
patient
show
recess
lossoffunct
mutat
lead
sever
immun
inflamm
calcif
polymicrogyria
defici
patient
repres
first
case
genet
disord
pt
caus
dysregul
respons
type
ifn
situat
make
interest
therapeut
target
agonist
might
strategi
dampen
typei
ifn
overabund
altern
antagonist
strategi
promot
degrad
could
promot
benefici
effect
therapeut
ifn
use
multipl
sclerosi
hairi
cell
leukemia
melanoma
meuwissen
et
al
studi
mice
lack
uncov
key
role
maintain
microgli
quiescenc
homeostat
condit
goldmann
et
al
schwabenland
et
al
neg
regul
activ
upon
interact
malakhova
et
al
interestingli
regulatori
function
independ
catalyt
activ
also
observ
knockin
mice
express
enzymat
inact
mice
show
increas
resist
viru
infect
contrast
mice
knockin
mice
display
fatal
ifn
hypersensit
brain
injuri
increas
lethal
ketscher
et
al
base
analysi
mice
select
inhibit
proteolyt
activ
might
use
antivir
strategi
gain
insight
target
would
interest
defin
modifi
protein
proteom
wide
base
isgylom
identifi
specif
modif
site
uncov
common
principl
modif
sever
proteom
studi
identifi
hundr
cellular
also
viral
substrat
giannakopoulo
et
al
zhao
et
al
studi
protein
purifi
cell
use
affin
select
mass
spectroscopi
msm
identifi
target
protein
later
new
studi
compar
proteom
bone
marrow
deriv
macrophag
bmdm
upon
vaccinia
viru
vacv
infect
baldanta
et
al
evalu
presenc
isgyl
protein
total
extract
bmdm
left
untreat
treat
ifn
vacv
result
indic
mitochondri
dysfunct
oxid
phosphoryl
oxpho
mice
baldanta
et
al
analysi
target
protein
shed
light
differ
function
innat
immun
system
recent
swatek
et
al
elucid
mechan
identifi
virusinduc
modifi
protein
upon
footandmouth
diseas
fmd
viral
leader
proteas
lbpro
mainli
target
show
high
activ
specif
ubl
protein
lbpro
cleav
peptid
bond
preced
ctermin
glygli
motif
consequ
cleav
longer
reconjug
lead
shut
modif
system
unlik
lbpro
cleavag
lead
recycl
sinc
cleav
isopeptid
linkag
ctermin
glygli
motif
remain
compet
reconjug
lbpro
activ
quantifi
use
fluoresc
polar
assay
reagent
swatek
et
al
importantli
lbpro
repres
new
tool
uncov
virusinduc
glygli
remnant
substrat
protein
use
antiglygli
antibodi
alreadi
use
ubiquitin
msm
research
peptid
enrich
immunoprecipit
ip
technolog
develop
quantit
profil
modif
site
cellular
protein
ubiquitin
well
ubl
coval
link
lysin
residu
target
protein
beadconjug
antibodi
specif
recogn
glygli
remnant
left
trypsin
digest
modifi
protein
udeshi
et
al
enrich
upon
antibodi
ip
coupl
liquid
chromatographi
lc
tandem
msm
analysi
lead
identif
substanti
number
protein
modifi
ubiquitin
ubl
ubiquitin
ubl
share
common
diglycin
adduct
upon
digest
trypsin
identif
sequenc
would
repres
valuabl
tool
character
new
molecular
pathway
situat
homeostasi
diseaserel
condit
recent
endogen
vivo
isgylom
mous
liver
follow
listeria
infect
map
studi
author
employ
antibodi
ip
wildtyp
mice
follow
lc
tandem
msm
analysi
comparison
dataset
allow
identifi
distinguish
isgyl
site
ubiquitin
site
vivo
zhang
et
al
similar
approach
alreadi
use
sever
cell
system
identifi
differ
posttransl
modif
phosphoryl
rush
et
al
ubiquitin
xu
et
al
kim
et
al
acetyl
weinert
et
al
kori
et
al
methyl
sumoyl
impen
et
al
lamoliatt
et
al
proteolysi
target
chimera
protac
degronimid
reagent
recruit
protein
interest
specif
ubiquitin
ligas
ligas
induc
ubiquitin
follow
subsequ
degrad
proteasom
probe
bifunct
small
molecul
combin
targetbind
warhead
ubiquitin
ligaserecruit
moieti
chemic
linker
sakamoto
et
al
stanton
et
al
drug
discoveri
strategi
differ
classic
method
focu
target
protein
interest
specif
inhibitor
receptor
ligand
interestingli
repres
first
oral
protac
drug
approv
fda
treatment
patient
metastat
castrationresist
prostat
cancer
protac
target
might
repres
interest
approach
specif
degrad
thu
enhanc
type
ifn
signal
besid
direct
destabil
target
interact
import
protein
might
constitut
option
interfer
function
sophist
techniqu
directli
studi
interact
within
cellular
context
bret
bioluminesc
reson
energi
transfer
assay
dipoledipol
energi
transfer
luciferas
fluorophor
success
energi
transfer
excit
spectrum
acceptor
fluorophor
overlap
bioluminesc
spectrum
gener
luciferas
ciruela
similar
fluoresc
reson
energi
transfer
fret
transfer
depend
close
proxim
nm
donoracceptor
pair
wu
brand
pfleger
eidn
thu
genet
fusion
system
protein
interest
use
measur
protein
interact
achiev
creat
fusion
construct
donor
luciferas
one
protein
interest
acceptor
second
protein
interest
case
repres
genet
modifi
luciferas
origin
deep
sea
shrimp
oplophoru
gracilirostri
act
donor
genet
engin
use
novel
coelenterazin
deriv
furimazin
result
brighter
luminesc
narrow
spectrum
higher
protein
stabil
compar
tradit
rluc
hall
et
al
acceptor
fusion
redemit
fluorophor
link
protein
machleidt
et
al
modifi
bacteri
haloalkan
dehydrogenas
coval
bind
fluoresc
dye
molecul
interest
chloroalkan
linker
allow
tailor
tag
individu
experiment
setup
lo
et
al
machleidt
et
al
multipl
strategi
propos
modul
function
immun
system
endogen
proteas
show
reactiv
toward
ubiquitin
malakhov
et
al
baster
et
al
ronau
et
al
repres
major
isopeptidas
vivo
neg
regul
type
ifn
precis
mediat
start
becom
clearer
recent
year
addit
protein
factor
involv
await
discoveri
moreov
unknown
whether
enzymat
nonenzymat
function
realli
exert
independ
manner
influenc
interact
assay
repres
techniqu
monitor
interact
involv
ifnar
close
cellbas
assay
appear
wellsuit
analyz
interact
two
protein
interest
physiolog
condit
nice
complement
biochem
assay
tradit
strategi
inhibit
enzym
activ
focus
develop
synthesi
small
molecul
bind
activ
side
protein
interest
order
decreas
activ
howev
besid
classic
biochem
proteas
assay
recombin
use
combin
baster
et
al
screen
system
suitabl
monitor
direct
bind
could
help
classic
approach
target
proteas
small
molecul
need
show
activ
toward
enzymat
activ
either
block
bind
pocket
alloster
mechan
highli
specif
requir
often
make
difficult
identifi
suitabl
compound
even
ht
approach
howev
librari
coval
inhibitor
could
benefici
chemic
screen
identifi
new
compound
protac
repres
eleg
strategi
target
difficult
druggabl
protein
select
target
degrad
proteasom
sakamoto
et
al
stanton
et
al
target
protein
low
affin
protac
still
target
degrad
long
format
protac
complex
gener
suffici
interact
target
protein
ligas
bondeson
et
al
therefor
import
consid
paramet
adequ
linker
specif
ligas
top
tradit
inhibitor
specif
describ
assay
repres
ht
compat
system
identifi
inhibitor
enzymat
activ
compound
identifi
screen
expect
bind
high
affin
even
coval
thu
also
constitut
interest
build
block
protac
aim
degrad
entir
protein
rather
stabil
isgyl
protac
direct
would
expect
also
boost
type
ifn
respons
longer
exert
neg
regulatori
function
ifnar
thu
target
degrad
might
least
conceptu
strategi
enhanc
therapeut
use
type
ifn
antivir
antineoblast
autoimmun
applic
current
sever
mous
model
studi
function
osiak
et
al
kim
et
al
ritchi
et
al
mice
ketscher
et
al
mice
lack
free
conjug
mice
show
higher
basal
induc
level
free
howev
mice
lack
conjug
mice
present
higher
basal
induc
level
modifi
protein
mous
express
catalyt
inact
form
thu
mimic
scenario
proteas
activ
repress
via
small
molecul
inhibitor
mous
model
show
enhanc
isgyl
level
proteas
inactiv
wherea
show
appar
phenotyp
alter
ketscher
et
al
furthermor
abnorm
identifi
mice
backcross
genet
background
mice
display
malform
lead
embryon
lethal
around
embryon
day
ketscher
et
al
use
human
mous
model
murin
replac
human
counterpart
would
repres
interest
vivo
model
studi
speciesspecif
differ
respect
substrat
recognit
antipathogen
activ
known
enzym
exchang
mous
human
effici
deconjug
isgyl
substrat
deriv
ifn
treat
human
cell
ketscher
et
al
therefor
mous
model
would
shed
light
murin
human
target
protein
upon
infect
differ
pathogen
conclus
use
differ
mous
model
combin
enrich
modifi
peptid
ip
msm
technolog
develop
quantit
profil
modif
site
cellular
protein
repres
valuabl
tool
unravel
isgylom
situat
homeostasi
diseaserel
condit
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
